Abstract: An aircraft assembly system includes a jig; and a position adjuster connected to the jig and configured to adjust a position of the jig, wherein the jig includes a ball stud between the jig and the position adjuster, and the position adjuster includes a socket in which at least a portion of the ball stud is accommodated and in which the ball stud is rotatably fastened.

Abstract: The present invention relates to a pharmaceutical composition for prevention and treatment of heart failure. Specifically, the present invention relates to a gene construct comprising a polynucleotide coding for SERCA2a protein or a fragment thereof and a polynucleotide coding for CCN5 protein or a fragment thereof, and a pharmaceutical composition comprising the same construct as an effective ingredient for preventing or treating heart failure. A pharmaceutical composition for prevention and treatment of heart failure according to the present invention is used in a method for co-expression of SERCA2a protein and CCN5 protein.

Abstract: The present specification provides: a method for generating a virtual organoid having various shapes and features; and a virtual organoid imaging method capable of obtaining the same effect as image data obtained from an actual organoid. The virtual organoid generation method according to the present specification may generate data relating to an organoid structure in a virtual space so as to apply the feature of an actual organoid. The imaging method using the virtual organoid according to the present specification enables generation of image data which can obtain the same effect as capturing an image of an actual organoid.

Abstract: In an assembly system of an aircraft including a fuselage and a wing, the aircraft assembly system may include: a jig unit coupled to the wing to move integrally with the wing; a transfer unit connected to the jig unit and transferring the wing toward the fuselage; a position adjusting unit detachably connected to the jig unit and adjusting a position of the jig unit; and a measuring unit configured for measuring positions of the fuselage and the wing, wherein the fuselage may be relatively fixed to the movement of the wing, wherein the measuring unit may be configured to set a fuselage coordinate system and a wing coordinate system for the fuselage and the wing, respectively, wherein the position adjusting unit may be configured to move the jig unit so that the wing coordinate system coincides with the fuselage coordinate system.

Abstract: A method for generating a virtual organoid having various shapes and characteristics; and a virtual organoid photographing method which can achieve the same effect as that of image data obtained by photographing a real organoid. The method for generating a virtual organoid according to the present specification may generate data about an organoid structure in a virtual space to reflect the characteristics of a real organoid. The photographing method using a virtual organoid according to the present specification may generate image data which can achieve the same effect as that achieved when photographing a real organoid.

Abstract: A cell culture plate according to one embodiment of the present invention is a cell culture plate which is formed by side walls and a bottom surface, includes a space containing a culture medium, has an open top, and is formed to be vertically stacked. The bottom surface includes a well area in which a plurality of wells are formed and a peripheral area formed around the well area, and the cell culture plate includes a culture medium flow hole formed through the bottom surface to allow a culture medium to flow in the peripheral area; a magnetic bead which is provided to open/close the culture medium flow hole by moving up and down due to a magnetic force, and formed of a material responding to magnetic force; and a bead holding space which forms a space allowing the movement of the magnetic bead and prevents the magnetic bead from being separated.

Abstract: A pharmaceutical composition suitable for preventing or treating cardiac arrhythmia is disclosed. The pharmaceutical composition contains, as an active ingredient, a CCN5 protein or a nucleotide encoding the CCN5 protein. The pharmaceutical composition inhibits the pathological activity of CaMKII, which induces cardiac electrical abnormalities that is the main cause of atrial arrhythmia and ventricular arrhythmia, so as to restore the electrical functions, and inhibits the activity of myofibroblasts causing structural abnormalities. Therefore, the pharmaceutical composition can be effectively used in the prevention or treatment of cardiac arrhythmia.

Abstract: A pharmaceutical composition containing, as active ingredients, a naphthoquinone-based compound, and at least one selected from among an immune checkpoint inhibitor and an immunogenic cell death inducer, is disclosed. The pharmaceutical composition has a significantly higher anticancer effect compared to the case where each formulation is administered alone. Accordingly, an anticancer synergistic effect of inhibiting the growth in cancer cells and inhibiting the metastasis of the cancer cells, in which an anticancer effect is insignificant when the existing anticancer agent is administered alone, may be expected. Therefore, the composition containing the naphthoquinone-based compound may be usefully used as a drug for preventing or treating cancer, together with the immune checkpoint inhibitor and/or the immunogenic cell death inducer.

Abstract: Disclosed are a compound represented by Formula (1) below, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R3,and Xi to X6 are the same as defined in claim 1.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in claim 1.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cardiac arrhythmia. Particularly, the present invention relates to a pharmaceutical composition containing, as an active ingredient, a CCN5 protein or a nucleotide encoding the same. The pharmaceutical composition for preventing or treating cardiac arrhythmia, of the present invention, inhibits the pathological activity of CaMKII, which induces cardiac electrical abnormalities which is the main cause of atrial arrhythmia and ventricular arrhythmia, so as to restore the electrical functions, and inhibits the activity of myofibroblasts causing structural abnormalities. Therefore, the pharmaceutical composition of the present invention can be effectively used in the prevention or treatment of cardiac arrhythmia.

Abstract: The present invention relates to a pharmaceutical composition for prevention and treatment of heart failure. Specifically, the present invention relates to a gene construct comprising a polynucleotide coding for SERCA2a protein or a fragment thereof and a polynucleotide coding for CCN5 protein or a fragment thereof, and a pharmaceutical composition comprising the same construct as an effective ingredient for preventing or treating heart failure. A pharmaceutical composition for prevention and treatment of heart failure according to the present invention is used in a method for co-expression of SERCA2a protein and CCN5 protein.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in claim 1.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in Claim 1.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R3, and X1 to X6 are the same as defined in Claim 1.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in Claim 1.

Abstract: The present invention relates to a composition for treating or preventing hearing loss comprising naphthoquinone-based compounds.

Abstract: A cooling system for a low pressure casting device, which includes an upper mold provided with a core portion of a spark plug and an upper die, a lower mold provided with a mold portion of a combustion chamber and a lower die, and side molds, may include i) a coolant supply unit connected respectively to the core portion of the spark plug, the upper die, the mold portion of the combustion chamber, and the lower die through coolant supply lines, ii) a cooling air supply unit connected respectively to the side molds and the mold portion of the combustion chamber through air supply lines, and iii) a vacuum intake unit connected respectively to the core portion of the spark plug, the upper die, the mold portion of the combustion chamber, and the lower die through vacuum intake lines.

Abstract: Provided is a composition that contains, as an active ingredient, an extract or polysaccharides separated from the leaves and/or stems of plants belonging to Panax genus, for an anticancer drug or its adjuvant, having an effect on the activity of hematopoiesis enhancement, cancer metastasis inhibition, bone marrow defense, etc. . . . , and a process for preparation of the extract from the leaves and/or stems of plants belonging to Panax genus.

Abstract: A cooling system for a low pressure casting device, which includes an upper mold provided with a core portion of a spark plug and an upper die, a lower mold provided with a mold portion of a combustion chamber and a lower die, and side molds, may include i) a coolant supply unit connected respectively to the core portion of the spark plug, the upper die, the mold portion of the combustion chamber, and the lower die through coolant supply lines, ii) a cooling air supply unit connected respectively to the side molds and the mold portion of the combustion chamber through air supply lines, and iii) a vacuum intake unit connected respectively to the core portion of the spark plug, the upper die, the mold portion of the combustion chamber, and the lower die through vacuum intake lines.